Post-Transplant Cyclophosphamide (PTCy) for GVHD Prophylaxis in HLA- Matched Related Donor HSCT in Pediatric and Adult Patients. Evidence of Real-Life Outcomes from a Latin American Transplant Center.

Key Points

• evidence supports the effectiveness of cyclophosphamide for GVHD prophylaxis in both pediatric and adult patients, enhancing transplant success.
• outcomes show improved GVHD rates post-transplant through the use of cyclophosphamide as a preventive measure.
• the observational analysis focused on a Latin American transplant center, providing insights into regional practices and outcomes.
• this approach may highlight the necessity for broader guidelines in GVHD management across different demographics.